Zhengye Biotechnology Holding (ZYBT) Total Non-Current Liabilities (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Total Non-Current Liabilities for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2025.

• Quarterly Total Non-Current Liabilities rose 95.82% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 95.82% YoY) and the FY2025 annual result came in at $1.3 million, up 101.82% from the prior year.
• Total Non-Current Liabilities grew to $1.3 million in Q4 2025 per ZYBT's latest filing, from $656000.0 in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ZYBT reached as high as $1.4 million in Q4 2023 and fell as low as $656000.0 in Q2 2025.
• A 3-year average of $1.0 million and a median of $988393.9 in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities slumped 53.66% — and 2025, when it jumped 95.82%.
• Year by year, Total Non-Current Liabilities stood at $1.4 million in 2023, then sank by 53.66% to $668235.5 in 2024, then soared by 95.82% to $1.3 million in 2025.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $1.3 million, $656000.0, and $668235.5 for Q4 2025, Q2 2025, and Q4 2024 respectively.